These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 23806289

  • 1. Dynamic transcriptomes of human myeloid leukemia cells.
    Wang H, Hu H, Zhang Q, Yang Y, Li Y, Hu Y, Ruan X, Yang Y, Zhang Z, Shu C, Yan J, Wakeland EK, Li Q, Hu S, Fang X.
    Genomics; 2013 Oct; 102(4):250-6. PubMed ID: 23806289
    [Abstract] [Full Text] [Related]

  • 2. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ, Yu YZ, Fang YM, Liang Y, Lü QH, Xu RZ.
    Zhonghua Yi Xue Za Zhi; 2005 Jul 20; 85(27):1903-6. PubMed ID: 16255985
    [Abstract] [Full Text] [Related]

  • 3. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV, Gerasimova LP, Sarkisian GP, Borovkova TV, Dukhovenskaia EA, Manakova TE, Naĭdenova NM, Timofeev AM, Grineva NI.
    Tsitologiia; 2007 Jul 20; 49(10):889-900. PubMed ID: 18074781
    [Abstract] [Full Text] [Related]

  • 4. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation.
    Gery S, Tanosaki S, Hofmann WK, Koppel A, Koeffler HP.
    Oncogene; 2005 Feb 24; 24(9):1589-97. PubMed ID: 15674331
    [Abstract] [Full Text] [Related]

  • 5. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
    Li J, Xue L, Hao H, Han Y, Yang J, Luo J.
    Oncol Rep; 2012 Feb 24; 27(2):461-6. PubMed ID: 21993902
    [Abstract] [Full Text] [Related]

  • 6. Epigenetic heterochromatin markers distinguish terminally differentiated leukocytes from incompletely differentiated leukemia cells in human blood.
    Popova EY, Claxton DF, Lukasova E, Bird PI, Grigoryev SA.
    Exp Hematol; 2006 Apr 24; 34(4):453-62. PubMed ID: 16569592
    [Abstract] [Full Text] [Related]

  • 7. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.
    Ruan GR, Qin YZ, Chen SS, Li JL, Ma X, Chang Y, Wang YZ, Fu JY, Liu YR.
    Leuk Res; 2006 Sep 24; 30(9):1159-65. PubMed ID: 16507320
    [Abstract] [Full Text] [Related]

  • 8. Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway.
    Zhang H, Tan S, Wang J, Chen S, Quan J, Xian J, Zhang Ss, He J, Zhang L.
    Exp Cell Res; 2014 Jan 01; 320(1):119-27. PubMed ID: 24076374
    [Abstract] [Full Text] [Related]

  • 9. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase.
    Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M, Brors B, Pechtel S, Bork S, Koch A, Baer A, Rohr UP, Kobbe G, von Haeseler A, Gattermann N, Haas R, Kronenwett R.
    Leukemia; 2007 Mar 01; 21(3):494-504. PubMed ID: 17252012
    [Abstract] [Full Text] [Related]

  • 10. Characterization of miRNomes in acute and chronic myeloid leukemia cell lines.
    Xiong Q, Yang Y, Wang H, Li J, Wang S, Li Y, Yang Y, Cai K, Ruan X, Yan J, Hu S, Fang X.
    Genomics Proteomics Bioinformatics; 2014 Apr 01; 12(2):79-91. PubMed ID: 24755403
    [Abstract] [Full Text] [Related]

  • 11. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.
    Oncogene; 2002 Nov 21; 21(53):8075-88. PubMed ID: 12444544
    [Abstract] [Full Text] [Related]

  • 12. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
    Peng Z, Luo HW, Yuan Y, Shi J, Huang SF, Li CL, Cao WX, Huang ZG, Feng WL.
    Oncol Rep; 2011 May 21; 25(5):1381-8. PubMed ID: 21369701
    [Abstract] [Full Text] [Related]

  • 13. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells.
    Li QF, Huang WR, Duan HF, Wang H, Wu CT, Wang LS.
    Oncogene; 2007 Dec 13; 26(57):7904-8. PubMed ID: 17599053
    [Abstract] [Full Text] [Related]

  • 14. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
    Chai SK, Nichols GL, Rothman P.
    J Immunol; 1997 Nov 15; 159(10):4720-8. PubMed ID: 9366395
    [Abstract] [Full Text] [Related]

  • 15. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H, Yan JS, Tao R, Hao SG, Liang H, Ma LY.
    Zhonghua Zhong Liu Za Zhi; 2012 Mar 15; 34(3):169-75. PubMed ID: 22780968
    [Abstract] [Full Text] [Related]

  • 16. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.
    Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536
    [Abstract] [Full Text] [Related]

  • 17. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF, Su YC, Zheng ZY, Jhih Cai C, Hou MH, Chao KS, Chen YJ.
    Biomed Pharmacother; 2012 Jul 15; 66(5):378-83. PubMed ID: 22397755
    [Abstract] [Full Text] [Related]

  • 18. STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells.
    Kiper HD, Tezcanli Kaymaz B, Gokbulut AA, Selvi N, Avci CB, Kosova B, Iskender G, Yandim MK, Gunduz C, Sahin F, Baran Y, Saydam G.
    Biomed Pharmacother; 2013 Jul 15; 67(6):527-32. PubMed ID: 23725755
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.
    Oncogene; 2002 Dec 12; 21(57):8804-16. PubMed ID: 12483533
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.